Reported 3 days ago
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has adjusted its outlook following management's announcement that it no longer expects any system replacements in the latter half of 2025, which led Wells Fargo to lower its price target from $75 to $58. The firm noted that with most of its systems being relatively new, the need for replacements has been overstated. PROCEPT focuses on urology surgical robotics, with its flagship AquaBeam Robotic System aimed at minimally invasive procedures.
Source: YAHOO